Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd Statistics
Share Statistics
Addex Therapeutics Ltd has 6.83K shares outstanding. The number of shares has increased by -0.66% in one year.
| Shares Outstanding | 6.83K |
| Shares Change (YoY) | -0.66% |
| Shares Change (QoQ) | -8.62% |
| Owned by Institutions (%) | 6.21% |
| Shares Floating | 6.83K |
| Failed to Deliver (FTD) Shares | 223 |
| FTD / Avg. Volume | 0.95% |
Short Selling Information
The latest short interest is 3.46K, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 3.46K |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.22% |
| Short Ratio (days to cover) | 0.14 |
Valuation Ratios
The PE ratio is -0.32 and the forward PE ratio is -152.2. Addex Therapeutics Ltd's PEG ratio is 0.
| PE Ratio | -0.32 |
| Forward PE | -152.2 |
| PS Ratio | 2.12 |
| Forward PS | 0 |
| PB Ratio | 2.98 |
| P/FCF Ratio | -0.43 |
| PEG Ratio | 0 |
Enterprise Valuation
Addex Therapeutics Ltd has an Enterprise Value (EV) of 374.45M.
| EV / Earnings | -35.47 |
| EV / Sales | 232.15 |
| EV / EBITDA | -36.61 |
| EV / EBIT | -36.42 |
| EV / FCF | -46.81 |
Financial Position
The company has a current ratio of 1.46, with a Debt / Equity ratio of 0.3.
| Current Ratio | 1.46 |
| Quick Ratio | 1.46 |
| Debt / Equity | 0.3 |
| Total Debt / Capitalization | 23.11 |
| Cash Flow / Debt | -23.21 |
| Interest Coverage | -477.21 |
Financial Efficiency
Return on equity (ROE) is -9.22% and return on capital (ROIC) is -690.11%.
| Return on Equity (ROE) | -9.22% |
| Return on Assets (ROA) | -2.27% |
| Return on Capital (ROIC) | -690.11% |
| Revenue Per Employee | $70,128.39 |
| Profits Per Employee | $-458,966.39 |
| Employee Count | 23 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -6.63% in the last 52 weeks. The beta is 1.94, so Addex Therapeutics Ltd's price volatility has been higher than the market average.
| Beta | 1.94 |
| 52-Week Price Change | -6.63% |
| 50-Day Moving Average | 7.78 |
| 200-Day Moving Average | 8.7 |
| Relative Strength Index (RSI) | 56.74 |
| Average Volume (20 Days) | 23.35K |
Income Statement
In the last 12 months, Addex Therapeutics Ltd had revenue of 1.61M and earned -10.56M in profits. Earnings per share was -0.14.
| Revenue | 1.61M |
| Gross Profit | -5.32M |
| Operating Income | -10.28M |
| Net Income | -10.56M |
| EBITDA | -10.23M |
| EBIT | -10.28M |
| Earnings Per Share (EPS) | -0.14 |
Balance Sheet
The company has 3.87M in cash and 344.34K in debt, giving a net cash position of 3.52M.
| Cash & Cash Equivalents | 3.87M |
| Total Debt | 344.34K |
| Net Cash | 3.52M |
| Retained Earnings | -360.42M |
| Total Assets | 12.17M |
| Working Capital | 3.18M |
Cash Flow
In the last 12 months, operating cash flow was -7.99M and capital expenditures -6.84K, giving a free cash flow of -8M.
| Operating Cash Flow | -7.99M |
| Capital Expenditures | -6.84K |
| Free Cash Flow | -8M |
| FCF Per Share | -0.11 |
Margins
Gross margin is -329.72%, with operating and profit margins of -639.27% and -654.47%.
| Gross Margin | -329.72% |
| Operating Margin | -639.27% |
| Pretax Margin | -654.47% |
| Profit Margin | -654.47% |
| EBITDA Margin | -634.16% |
| EBIT Margin | -637.42% |
| FCF Margin | -495.94% |
Dividends & Yields
ADXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.66% |
| FCF Yield | -13864.24% |
Analyst Forecast
The average price target for ADXN is $30, which is 255% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 255% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 23, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Oct 23, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -41.92 |
| Piotroski F-Score | 5 |